Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Ovarian Cancer Recurrent × Lenalidomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 237 Lymphoma, Large B-Cell, Diffuse 59 Leukemia, Lymphocytic, Chronic, B-Cell 59 Neoplasms, Plasma Cell 44 Lymphoma, Follicular 42 Lymphoma, Mantle-Cell 39 Lymphoma 38 Recurrence 35 Lymphoma, B-Cell, Marginal Zone 31 Leukemia 28 Leukemia, Myeloid, Acute 25 Lymphoma, B-Cell 18 Myelodysplastic Syndromes 16 Waldenstrom Macroglobulinemia 15 Lymphoma, Non-Hodgkin 15 Smoldering Multiple Myeloma 12 Hodgkin Disease 12 Lymphoma, T-Cell, Peripheral 10 Neoplasms 9 Prostatic Neoplasms 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Lymphoma, T-Cell, Cutaneous 8 Immunoglobulin Light-chain Amyloidosis 8 Burkitt Lymphoma 8 Sezary Syndrome 7 Mycosis Fungoides 7 Neoplasm, Residual 6 Lymphoma, T-Cell 6 Lymphoma, Large-Cell, Anaplastic 6 Intraocular Lymphoma 6

Interventions

poly(I).poly(c12,U) 1 pembrolizumab 1 mirabegron 1 liposomal doxorubicin 1 disitamab vedotin 1 apatinib 1 anlotinib 1 Tocotrienols 1 Platinum Compounds 1 Paclitaxel 1 Lenalidomide 1 Interferon alpha-2 1 Hyperthermic Intraperitoneal Chemotherapy 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01111903 2016-03-17

REV

ARCAGY/ GINECO GROUP

Phase 1/2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡